| Submission to first decision
(The average time from manuscript submission to desk rejection, direct rejection/acceptance or assignment to the first editor) Note: For manuscripts that fully comply with the journal template. However, this timeframe does not apply to manuscripts with formatting or guideline deficiencies. If a manuscript is returned to the authors for corrections, the administrative review process will restart from the re-submission date. |
3 weeks |
|---|---|
| Submission to decision after review (For papers that are sent to review, the average time from submission to receipt of first editor decision) | 6 weeks |
| Submission to final decision (The average time from manuscript submission to the final editorial decision) | 16 weeks |
| Submission to publication (The average time from acceptance to publication. Manuscript published in early view are also included in this calculation) | 24 weeks |
ACTA Pharmaceutica Sciencia
2026 , Vol 64 , Num 4
Differential apoptosis-associated responses of neurons and glial cells to cisplatin in primary cortical cultures
1 İstanbul Medipol University, Regenerative and Restorative Medicine Research Center (REMER), Research Institute for Health Sciences and Technologies (SABITA), İstanbul, Türkiye2 İstanbul Medipol University, Graduate School of Health Sciences, Istanbul, Türkiye
3 İstanbul Medipol University, School of Medicine, Department of Medical Biology, Istanbul, Türkiye
DOI : 10.23893/1307-2080.APS64030 Viewed : 620 - Downloaded : 276 Cisplatin is a platinum-based chemotherapeutic agent widely used to treat solid tumors; however, its clinical use is limited by severe neurotoxicity. Although cisplatin shows limited blood–brain barrier permeability, accumulating evidence indicates that it induces apoptosis-associated neurotoxicity in the central nervous system. In this study, we investigated cell type–specific apoptosis-associated responses of primary cortical neurons and glial cells to cisplatin. Cytotoxicity was evaluated in EMT6 murine mammary carcinoma cells using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, and the half-maximal inhibitory concentration (IC₅₀) was determined. This concentration was then applied to primary cortical cultures derived from postnatal day 0 Balb/C mice. Apoptosis-associated responses were assessed by Western blot analysis of BCL-2 expression and immunofluorescence staining of caspase-3. Cisplatin significantly reduced BCL-2 protein levels in primary cortical cultures (p<0.01). Immunofluorescence analysis further revealed a significant increase in caspase-3–positive neurons following cisplatin exposure (p<0.01), whereas no significant change was observed in GFAP-positive glial cells (p>0.05). These findings demonstrate that cisplatin induces cell type–specific apoptosis-associated responses in primary cortical cultures, with neurons showing greater vulnerability than glial cells, highlighting the importance of evaluating cisplatin-induced neurotoxicity in the central nervous system. Keywords : cisplatin, neurotoxicity, apoptosis, caspase 3, cerebral cortex
